STOCK TITAN
  1. Home
  2. News
  3. PTGX

Protagonist Therapeutics, Inc - PTGX STOCK NEWS

Welcome to our dedicated page for Protagonist Therapeutics news (Ticker: PTGX), a resource for investors and traders seeking the latest updates and insights on Protagonist Therapeutics stock.

Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to discover and develop novel peptide-based drugs. The company's primary focus is on creating first-in-class oral targeted therapies that inhibit biological pathways currently addressed by injectable antibody drugs. This innovative approach aims to treat significant unmet medical needs, particularly in the areas of inflammatory bowel disease (IBD) and other autoimmune diseases.

Protagonist's lead peptide product candidates, PTG-100 and PTG-200, are designed to transform treatment paradigms for conditions such as ulcerative colitis and Crohn's disease. PTG-100, an oral peptide alpha-4-beta-7 integrin antagonist, is in a global Phase 2b clinical trial for moderate-to-severe ulcerative colitis. PTG-200, a first-in-class oral interleukin-23 receptor antagonist, is also progressing through clinical trials.

Another key asset, JNJ-2113 (formerly PN-235), achieved primary and secondary endpoints in the Phase 2b FRONTIER 1 trial for moderate-to-severe plaque psoriasis. This drug is part of an extensive clinical development program, including multiple Phase 3 studies under the ICONIC program. JNJ-2113 is also being evaluated in a Phase 2b ANTHEM-UC study for ulcerative colitis.

Protagonist's pipeline also includes Rusfertide (PTG-300), an injectable hepcidin mimetic currently in Phase 3 development for polycythemia vera. The REVIVE Phase 2 study demonstrated that rusfertide effectively maintains hematocrit control and reduces the need for phlebotomies in patients.

The company has established significant partnerships to further its clinical programs. Notably, Protagonist collaborates with Johnson & Johnson and Takeda Pharmaceuticals to co-develop and co-commercialize its lead candidates, expanding its reach and impact in the biopharmaceutical landscape.

Protagonist continues to drive innovation with its ongoing discovery efforts, aiming to develop additional oral peptides targeting validated biological pathways. With a robust pipeline and strategic collaborations, Protagonist Therapeutics is poised to make substantial contributions to the treatment of autoimmune and hematological diseases.

News

Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis

Rhea-AI Summary
Protagonist Therapeutics, Inc. (PTGX) announced it has earned a $10 million milestone payment following the dosing of the third patient in ANTHEM-UC, a Phase 2b trial to evaluate the safety and effectiveness of JNJ-2113 compared with placebo in participants with moderately to severely active ulcerative colitis. With this additional payment, the Company has now earned $60 million in payments in the fourth quarter of 2023 for milestones achieved in the JNJ-2113 Phase 2b and Phase 3 clinical programs led by the Company's collaboration partner, Janssen Biotech, Inc., a Johnson & Johnson company. The Company remains eligible for up to an additional $795 million in other development and sales milestone payments with respect to JNJ-2113 or other licensed IL-23 receptor antagonist oral peptides.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.83%
Tags
clinical trial
-
News

Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals

Rhea-AI Summary
Protagonist Therapeutics, Inc. (PTGX) presented long-term follow-up data from the REVIVE Phase 2 study and other analyses at the American Society of Hematology 2023 Annual Meeting. The data showed durable hematocrit control, decreased phlebotomy use, long-term tolerability, and no new safety signals in patients with polycythemia vera. Rusfertide, a mimetic of the natural hormone hepcidin, demonstrated potential therapeutic value in treating PV and other diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.8%
Tags
none
-
News

Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with Deucravacitinib

Rhea-AI Summary
Protagonist Therapeutics, Inc. (PTGX) announced the addition of two Phase 3 studies, ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2, evaluating JNJ-2113 in head-to-head comparisons against deucravacitinib in patients with moderate-to-severe psoriasis. The company is eligible to receive a $115 million milestone payment upon achieving co-primary endpoints in any of the studies. JNJ-2113 is a targeted oral peptide designed to selectively block the IL-23 receptor, and the Phase 3 program aims to establish it as the preferred oral treatment option for psoriasis patients. Protagonist has a license and collaboration agreement with Janssen for the development and commercialization of JNJ-2113, earning milestone payments upon successful milestones and eligible for additional development and sales milestone payments. The company also retains upward tiering royalties of 6%-10% for net sales of JNJ-2113.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.1%
Tags
clinical trial
News

Protagonist Therapeutics Reports Granting of Inducement Awards

Rhea-AI Summary
Protagonist Therapeutics, Inc. (Nasdaq:PTGX) issued inducement awards to two new employees, granting them options to purchase 50,000 shares of the company's common stock at an exercise price of $16.29. The options vest over a four-year period, with 25% vesting on the first anniversary of hire and the remainder in equal monthly installments over three years. The awards were granted in accordance with the Protagonist Therapeutics Amended and Restated Inducement Plan and approved by the compensation committee as a material inducement to employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.28%
Tags
none
-
News

Protagonist Therapeutics Ranked in the Top 3% of Fastest-Growing Companies in North America on the 2023 Deloitte Technology Fast 500(TM)

Rhea-AI Summary
Protagonist Therapeutics (Nasdaq:PTGX) ranked in the top 3% of the 2023 Deloitte Technology Fast 500TM, showcasing impressive revenue growth fueled by a novel oral peptide therapeutic program. The company's CEO expressed pride in the recognition and highlighted the dedication of the team and strength of partnerships.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.82%
Tags
none
-
News

Protagonist Therapeutics Announces Abstracts Selected for Oral and Poster Presentations at the American Society of Hematology 2023 Annual Meeting

Rhea-AI Summary
Protagonist Therapeutics, Inc. announced that five abstracts related to their rusfertide program have been accepted for presentation at the 65th American Society of Hematology Annual Meeting and Exposition. The presentations will cover data on the potential of rusfertide in the treatment of Polycythemia Vera and other disease indications. The company will also present data on the epidemiological aspects of Polycythemia Vera and preclinical data on the treatment of sickle cell disease with a hepcidin mimetic. The presentations are expected to make significant contributions to the field of hematology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.99%
Tags
none
News

Protagonist Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Rhea-AI Summary
Protagonist Therapeutics reports positive Phase 2b results for JNJ-2113, an oral IL-23 receptor antagonist peptide drug candidate for plaque psoriasis. The company plans to advance with two Phase 3 studies in psoriasis and a Phase 2b study in ulcerative colitis. Cash runway is forecasted through Q1 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.99%
Tags
earnings
-
News

Protagonist Announces Achievement of $50M Milestone Event After Third Patient is Dosed in Phase 3 Study of JNJ-2113 in Moderate-to-Severe Psoriasis

Rhea-AI Summary
Protagonist Therapeutics achieves $50 million milestone event in collaboration with Janssen Biotech for the development of JNJ-2113 in psoriasis. The ICONIC Phase 3 program is progressing rapidly, and additional Phase 3 studies are planned for JNJ-2113. ANTHEM UC Phase 2b study for ulcerative colitis is also underway.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.92%
Tags
clinical trial
-
News

Protagonist Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary
Protagonist Therapeutics, Inc. announced that its CEO will participate in investor conferences this month. The conferences include Guggenheim 5th Annual I&I Conference, J.P. Morgan Equity Opportunities Forum, Truist Securities BioPharma Symposium, and Jefferies London Healthcare Conference. Company presentations will be available on the Protagonist corporate website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.92%
Tags
conferences
News

Protagonist Therapeutics Announces Appointment of Daniel Swisher to Its Board of Directors

Rhea-AI Summary
Protagonist Therapeutics has announced the appointment of Daniel N. Swisher, Jr. to its Board of Directors. Mr. Swisher recently retired as President and COO of Jazz Pharmaceuticals. Protagonist has two late-stage assets in Phase 3 development, JNJ-2113 and rusfertide, which offer significant growth opportunities for the company. Mr. Swisher's experience in leading biotech companies will provide valuable perspective and insight to Protagonist.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.82%
Tags
management

FAQ

What is the current stock price of Protagonist Therapeutics (PTGX)?

The current stock price of Protagonist Therapeutics (PTGX) is $39.3 as of December 24, 2024.

What is the market cap of Protagonist Therapeutics (PTGX)?

The market cap of Protagonist Therapeutics (PTGX) is approximately 2.3B.

What is Protagonist Therapeutics' main focus?

Protagonist Therapeutics focuses on developing novel peptide-based drugs to address significant unmet medical needs, particularly for inflammatory bowel disease and autoimmune diseases.

What are PTG-100 and PTG-200?

PTG-100 is an oral peptide alpha-4-beta-7 integrin antagonist currently in Phase 2b trials for ulcerative colitis. PTG-200 is a first-in-class oral interleukin-23 receptor antagonist being developed for Crohn's disease.

What is JNJ-2113?

JNJ-2113 (formerly PN-235) is a targeted oral peptide designed to block the IL-23 receptor, currently being evaluated in multiple Phase 3 studies for moderate-to-severe plaque psoriasis and a Phase 2b study for ulcerative colitis.

What is rusfertide (PTG-300)?

Rusfertide is an injectable hepcidin mimetic in Phase 3 development for polycythemia vera. It has shown effectiveness in controlling hematocrit levels and reducing the need for phlebotomies.

Who are Protagonist's collaboration partners?

Protagonist collaborates with Johnson & Johnson and Takeda Pharmaceuticals to co-develop and co-commercialize its lead drug candidates.

What recent achievements has Protagonist announced?

Protagonist reported that JNJ-2113 met all primary and secondary endpoints in the Phase 2b FRONTIER 1 trial and is now in multiple Phase 3 studies. They also entered a significant partnership with Takeda Pharmaceuticals.

What is Protagonist's proprietary technology platform?

Protagonist's proprietary technology platform enables the discovery and development of novel constrained peptide-based drug candidates.

What are the latest developments in Protagonist's clinical trials?

Protagonist has ongoing Phase 3 trials for JNJ-2113 in psoriasis and a Phase 2b trial in ulcerative colitis, as well as a Phase 3 trial for rusfertide in polycythemia vera.

What is the status of the rusfertide Phase 3 VERIFY trial?

The Phase 3 VERIFY trial is nearing completion of enrollment, with top-line data expected by the first quarter of 2025.

Where can I find more information about Protagonist's drug candidates and clinical studies?

More information about Protagonist Therapeutics, its pipeline drug candidates, and clinical studies can be found on the company's website at www.protagonist-inc.com.

Stock PTGX logo
Protagonist Therapeutics, Inc

Nasdaq:PTGX

PTGX Rankings

#1860 Ranked by Market Cap
N/A Ranked by Dividends

PTGX Stock Data

2.34B
57.43M
1.13%
107.25%
5.54%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEWARK